Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional <scp>AUSTRO</scp> ‐ <scp>PROFIT</scp> study
The AUSTRO-PROFIT study revealed notable variations in metabolic targets achievement with respect to clinical characteristics and comorbidities. These findings underscore the importance of establishing national diabetes registries and implementing multifactorial targeted and individualized interventions to further improve the quality of T2D care in primary care settings in Austria.
Authors
- Faisal Aziz (ORCID: https://orcid.org/0000-0002-0109-2969)
- Gersina Rega‐Kaun (ORCID: https://orcid.org/0000-0002-3110-481X)
- Bernhard Ludvik (ORCID: https://orcid.org/0009-0003-8717-8396)
- Lars Stechemesser
- Julia Katharina Mader (ORCID: https://orcid.org/0000-0001-7854-4233)
- Harald Kojzar (ORCID: https://orcid.org/0000-0002-9742-439X)
- Harald Sourij (ORCID: https://orcid.org/0000-0003-3510-9594)
- Martin Clodi (ORCID: https://orcid.org/0000-0003-2177-0891)
- Michael Resl (ORCID: https://orcid.org/0000-0002-1702-8945)
- Norbert J. Tripolt (ORCID: https://orcid.org/0000-0002-7566-2047)
- Susanne Kaser (ORCID: https://orcid.org/0000-0003-2524-5218)
- Kehkishan Azhar
- Caren Sourij (ORCID: https://orcid.org/0000-0003-1688-4026)
- Claudia Ress (ORCID: https://orcid.org/0009-0008-0215-2549)
- Harald Stingl
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-1709-1079)
- Thomas C. Wascher
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- Paracelsus Medical University (AT)
- Hanusch Hospital (AT)
- Convent Hospital of the Brothers of Saint John of God (AT)
- Karl Landsteiner Society (AT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1111/dom.15988
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Novo Nordisk Foundation Center for Basic Metabolic Research
- Österreichische Diabetes Gesellschaft
- Novartis Pharma
- Roche Diagnostics
- Daiichi Sankyo Europe